深圳市建筑科学研究院股份有限公司 监事会 证券代码：300675 证券简称：建科院 公告编号：2025-021 深圳市建筑科学研究院股份有限公司 公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 监事会会议召开情况 深圳市建筑科学研究院股份有限公司（以下简称公司）第四届监事会第六次 临时会议通知于 2025 年 6 月 6 日以电子邮件方式送达各位监事。会议由监事会 主席余述胜先生召集及主持，在保障所有监事充分表达意见的情况下，以通讯表 决方式召开并于 2025 年 6 月 9 日完成表决，应到监事 5 名，实到监事 5 名。 会议的召开符合《中华人民共和国公司法》 《中华人民共和国证券法》 《公司 章程》及《公司监事会议事规则》等相关规定。会议通过如下决议： 监事会会议审议情况 会议通过如下决议： 审议通过《公司 2025 年度全面预算案》 监事会同意《公司 2025 年度全面预算案》。 具体内容详见公司于同日在巨潮资讯网（http://www.cninfo.com.cn，下同） 披露的《公司 2025 年度全面预算案》（公告编号：2025-022）。 表决结果 ...

Core Viewpoint - The recent control change transaction at Filinger has sparked market speculation due to governance issues and potential insider trading allegations, raising questions about whether this is a genuine governance restructuring or a maneuver to escape scrutiny [2][5]. Group 1: Control Change Transaction - Filinger's actual controller Ding Furu and his associates signed a share transfer agreement with Anji Yiqing and its controller Jin Yawei, transferring approximately 88.87 million shares at a price of 7.88 yuan per share, accounting for 25% of the company's total equity [3]. - Another agreement was made by Filinger's major shareholder to transfer about 96.76 million shares at a price of 6.73 yuan per share, representing 27.22% of the total equity [3]. - Filinger's stock price surged to a limit-up of 8.22 yuan per share on the day of the announcement, marking a new high since May 2020, while most peers in the industry saw declines [3][5]. Group 2: Governance Issues - Filinger has faced internal governance conflicts, with the chairman expressing doubts about the authenticity of annual reports for two consecutive years and proposing changes in the CEO multiple times [2][9]. - The company has been under scrutiny for failing to disclose related party transactions properly, leading to regulatory warnings and penalties [9]. - Filinger's revenue has significantly declined from 782 million yuan in 2021 to 336 million yuan in 2024, with net losses reported for two consecutive years, including a loss of 37.31 million yuan in 2024, a year-on-year decrease of 54.26% [9].

健康元 药业集团股份有限公司(股票代码：600380)于2025年6月6日在深圳市南山区召开2024年年度股东 大会，会议以现场结合网络投票方式举行，出席股东持股比例达51.11%。大会审议通过了包括董事会 工作报告、财务决算报告、利润分配方案等10项议案，其中现金分红方案获99.91%高票通过，持股5% 以上股东全票支持。 核心决议： 1.利润分配：2024年度利润分配方案获通过，中小投资者支持率达97.9%，市值50万以下股东赞成比例 98.39%。 2.融资担保：公司授信融资及为子公司提供担保的议案以97.66%赞成率通过，但中小投资者分歧较大 (赞成率44.38%)。 3.审计续聘：续聘致同会计师事务所为2025年审计机构，赞成率99.74%。 会议程序符合《公司法》及公司章程，由董事林楠棋主持，董事会全体成员及监事出席。北京德恒(深 圳)律师事务所对会议合法性出具无异议意见。 关键数据： 影响范围： -总表决股份数9.35亿股，占公司总股本51.11%。 决议明确了公司2024年财务分配及2025年融资担保框架，强化了对子公司风险管控，同时延续审计机构 稳定性，为投资者传递稳健经营信号。中小投资者在 ...

Group 1 - The company plans to deregister its Xiangxiang branch to enhance overall strategic planning, optimize resource allocation, and reduce management costs, thereby improving operational efficiency and overall business performance [1][5] - The Xiangxiang branch was established on May 27, 2004, and its business scope included the breeding and sale of fat pigs and breeding pigs, as well as consulting on breeding technology and the sale of feed additives [2] - The board of directors approved the deregistration proposal with a unanimous vote of 7 in favor, 0 against, and 0 abstentions during the 17th meeting of the 6th board on June 6, 2025 [3] Group 2 - The deregistration of the Xiangxiang branch will not affect the company's business development or profitability and will not harm the interests of the company or its shareholders, especially minority shareholders [5] - The deregistration does not involve related transactions and does not constitute a major asset restructuring [4]

Core Viewpoint - The company has revised its governance structure by abolishing the supervisory board and transferring its responsibilities to the audit committee, aiming to enhance operational efficiency and compliance with regulatory requirements [1][2]. Summary by Sections Audit Committee - The audit committee's main responsibilities include proposing the hiring or replacement of external auditors, supervising the internal audit system, and reviewing financial information and internal control systems [1][2]. - Decisions regarding hiring or dismissing the auditing firm and financial officer require a majority approval from the audit committee [2]. Nomination Committee - The nomination committee is responsible for proposing standards and procedures for selecting directors and senior management, as well as reviewing candidates for these positions [3][4]. - The committee must document and disclose reasons if the board does not adopt its recommendations [4]. Compensation and Assessment Committee - This committee is tasked with establishing assessment standards for directors and senior management, as well as reviewing and proposing compensation policies [5][6]. - Any proposed compensation plans must be approved by the board and then submitted to the shareholders' meeting for approval [6]. Strategic and Sustainable Development Committee - The strategic committee can invite directors and senior management to its meetings and is responsible for overseeing investment evaluations [6]. - The committee's operational guidelines will take effect upon board approval [6]. General Amendments - The term "shareholders' meeting" has been standardized to "shareholders' assembly" across all revised documents, with no substantial changes to other provisions [6].

Group 1 - The Strategic and Sustainable Development Committee is established to enhance the company's core competitiveness and ensure effective investment decision-making [2][4] - The committee consists of three directors, including at least one independent director, and is responsible for long-term strategic planning and oversight of major investment decisions [2][4] - The committee's decisions must be approved by a majority of its members and are submitted to the board for final approval [4][2] Group 2 - The committee is tasked with managing sustainable development initiatives and reviewing ESG reports [2][4] - An Investment Review Group is set up under the committee to prepare proposals for major investments and capital operations [2][4] - Meetings require the presence of at least two-thirds of the committee members to be valid, and decisions are made through voting [4][2]

中国出版传媒股份有限公司 股东会议事规则 中国出版传媒股份有限公司股东会议事规则 目 录 中国出版传媒股份有限公司股东会议事规则 中国出版传媒股份有限公司 股东会议事规则 第一章 总则 第一条 为了维护全体股东的合法权益，规范中国出版传媒股份有限公司（以下 简称"公司"或"本公司"）的行为，保证公司股东会规范、高效运作，确保股东平等、 有效地行使权利，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民 共和国证券法》（以下简称《证券法》）、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 《上市公司治理准则》 《上市公司股东会规则》 《中国出版传媒股份有 限公司章程》（以下简称《公司章程》）及其他有关法律法规的规定，制定本规则。 第二条 公司应当严格按照法律、行政法规、公司章程和本规则的相关规定召开 股东会，保证股东能够依法行使权利。公司董事会应当切实履行职责，认真、按时组 （二） 审议、批准董事会的报告； （三） 审议、批准公司的利润分配方案和弥补亏损方案； 中国出版传媒股份有限公司股东会议事规则 织股东会。公司全体董事应当勤勉尽责，确保股东会正常召开和依法行使职权。 股东会可以授权 ...

市公司章程指引（2025 年修订）》修订《公司章程》及相关议事规则，结合公司 实际情况，公司将不再设置监事会，监事会职权由董事会审计委员会行使，《监 事会议事规则》相应废止，现修订《公司章程》 《股东大会议事规则》 《董事会议 证券代码：603214 证券简称：爱婴室 公告编号：2025-031 上海爱婴室商务服务股份有限公司 关于取消监事会并修订《公司章程》 及相关议事规则的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步规范公司运作，完善公司治理，根据《中华人民共和国公司法》 《上 事规则》相应条款，主要内容涉及：删除关于监事、监事会相关规定，由审计委 员会行使监事会职权；涉及"股东大会"的表述统一修订为"股东会"等。具体 修订条款明细如下： 一、《公司章程》修订明细 原条款 修改后条款 第十条 本公司章程自生效之日起，即成为 第十条 本公司章程自生效之日起，即 规范公司的组织与行为、公司与股东、股 成为规范公司的组织与行为、公司与股 东与股东之间权利义务关系的具有法律约 东、股东与股东之间权利义务关系的具 ...

沈阳芯源微电子设备股份有限公司 章 程 目 录 沈阳芯源微电子设备股份有限公司 章 程 第一章 总 则 第一条 为维护沈阳芯源微电子设备股份有限公司（以下简称"公司"）、 股东、职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和 国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证 券法》）、《科创板上市公司持续监管办法（试行）》《上海证券交易所科创板 股票上市规则》《上市公司章程指引》等法律法规和其他有关规定，制定本章程。 第二条 公司系依照《公司法》《证券法》及其他法律法规的规定成立的股 份有限公司。 公司由沈阳芯源微电子设备有限公司整体变更设立，在沈阳市浑南区市场监 督管理局注册登记，取得营业执照，统一社会信用代码为：9121011274273568XC。 第三条 公司于 2019 年 11 月 15 日经中国证券监督管理委员会（以下简称 "中国证监会"）作出同意注册决定，首次向社会公众发行人民币普通股 2,100 万股，于 2019 年 12 月 16 日在上海证券交易所科创板上市。 第四条 公司注册名称 第七条 公司为永久存续的股份有限公司，经营期限为长期。 第八条 ...

Board Meeting Overview - The fifth meeting of the fifth board of directors of Qingdao Guoen Technology Co., Ltd. was held on June 6, 2025, with all seven directors present and voting [1] - The meeting was convened by Chairman Wang Aiguo and followed legal procedures as per the Company Law and the company's articles of association [1] Board Resolutions - The board approved the appointment of Mr. Wang Long as the deputy general manager, effective from the date of the board's approval until the end of the current board's term [2] - The board reviewed and approved several internal governance documents, including: - Strategic Committee Work Rules [2] - Audit Committee Work Rules [2] - Nomination Committee Work Rules [2] - Compensation and Assessment Committee Work Rules [2] - Independent Director Annual Report Work System [3] - Information Disclosure Management System [3] - Investor Relations Management System [3] - Insider Information Knowledge Person Registration Management System [3] - Major Information Internal Reporting System [3] - Management System for Shares Held by Directors and Senior Management [3] - Secretary of the Board Work Rules [3] - Internal Audit System [3] - Specific Object Reception and Promotion Work System [3] - Subsidiary Management System [3] - General Manager Work Rules [3] - Fundraising Management System [3] - Goodwill Impairment Testing Internal Control System [3] - Information Disclosure Delay and Exemption Management System [3] - Management System for Resignation of Directors and Senior Management [3] Governance Structure Improvement - The company aims to enhance its governance structure in compliance with domestic and international laws and regulations, particularly in relation to its H-share listing [4] - The board authorized management to adjust and modify governance documents as necessary based on regulatory changes and actual circumstances surrounding the H-share issuance [4] Effective Date of Resolutions - The approved governance documents will take effect upon the listing of the company's H-shares on the Hong Kong Stock Exchange, with existing governance documents being repealed simultaneously [5]